The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis

@article{Lynch2010TheSA,
  title={The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis},
  author={Patrick M. Lynch and Gregory Daniel Ayers and Ernie Hawk and Ellen Richmond and Craig J. Eagle and Mabel Woloj and James Church and Hennie Hasson and Sherri Patterson and Elizabeth Half and Carol Ann Burke},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105},
  pages={1437-1443}
}
OBJECTIVES:Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP). Its safety and efficacy for colorectal polyps in children is unknown. We evaluated the short-term (3 months) safety and preliminary efficacy of celecoxib in children with FAP.METHODS:This was a phase I, dose-escalation trial, with three successive cohorts of six children. Children of ages 10–14 years with APC gene mutations and/or adenomas with a family history of FAP… CONTINUE READING
28 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Cytochrome P 450 2 C 9 variants infl uence response to celecoxib for prevention of colorectal adenoma

  • AT Chan, AG Zauber, M Hsu
  • Gastroenterology
  • 2009

Th e eff ect of celecoxib , a cyclooxygenase2 inhibitor , in familial adenomatous polyposis

  • G Steinbach, PM Lynch, RK Phillips
  • N Engl J Med
  • 2000

Similar Papers

Loading similar papers…